查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403488

2030 年前列腺癌诊断市场预测：按测试类型、癌症类型、最终用户和地区进行的全球分析

Prostate Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Test Type, Cancer Type, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球前列腺癌诊断市场规模为 87.7 亿美元，预计 2030 年将达到 152.5 亿美元，预测期内复合年增长率为 8.23%。

前列腺癌诊断采用多方面的方法来识别和描述阶段前列腺癌。直肠指检 (DRE)、超音波(TRUS)、磁振造影(MRI) 和摄护腺特异性抗原 (PSA) 血液检查是重要的诊断技术。此外，PSA 测试可测量前列腺分泌的蛋白质量，高水平通常表示需要进行额外的测试。直肠指检可有效评估前列腺的大小和质地。

根据美国美国癌症研究所的数据，2019 年美国新诊断出超过 174,650 例前列腺癌。此外，根据相同来源的资料，2019 年有超过 31,620 人死于摄护腺癌。

摄护腺癌发生率增加

癌症检测技术的进步、人口高龄化和生活方式的改变是前列腺癌发生率在全球范围内稳步上升的主要原因。此外，对能够在阶段准确识别和表征前列腺癌的先进诊断工具的需求日益增长，并且随着筛检计划的广泛实施和医疗保健意识的提高，市场不断增长，这是其背后的驱动力。

昂贵的神经影像设备

由于磁振造影(MRI) 等先进神经影像设备的成本高昂，医疗机构面临巨大的财务障碍。购买和维护最先进的设备所需的大量资本支出可能会限制对高级诊断工具的访问，尤其是在资源有限的环境中。此外，需要创造性的资金筹措策略和负担得起的替代方案来缓解这一限制。

神经影像技术发展

只要神经影像成像技术不断进步，市场就会大幅成长。脑磁图 (MEG)、正子断层扫描 (PET) 和功能性磁振造影(fMRI) 等诊断技术的进步为提高灵敏度、解析度和诊断能力提供了机会。此外，投资研究和开发以整合这些最尖端科技可以为准确和深入的神经成像创造新的机会。

来自替代诊断技术的威胁

传统的神经影像学正受到新的和替代诊断技术的威胁，例如可穿戴神经技术和脑脊髓液生物标记分析。此外，市场的既定地位正受到非成像方式的威胁，需要持续创新和差异化才能保持相关性并维持市场占有率。

COVID-19 的影响：

COVID-19 的爆发对神经影像市场产生了重大影响。全球健康危机的突然爆发扰乱了常规诊断测试、选择性筛检和非紧急就诊等医疗服务。随着社会疏离措施的落实以及为流行病管理分配资源，神经影像学的使用减少。此外，医疗机构的采购能力受到供应链中断和经济不确定性的影响，从而推迟了最先进的诊断成像设备的购买。

预计在预测期内前列腺腺癌将是最大的

市场占有率最大的细分市场是前列腺癌。大多数诊断出的前列腺癌病例是前列腺癌。前列腺腺泡细胞是癌症的起源部位，其表现为多种临床和侵袭性形式。年龄、遗传和荷尔蒙影响是与前列腺腺癌高发生率相关的因素。此外，如果不使用 PSA 测试、直肠指检 (DRE) 和先进成像技术等诊断技术，前列腺腺癌就很难诊断和表征。

诊断测试产业预计在预测期内复合年增长率最高。

在市场上，复合年增长率最高的细分市场是诊断实验室。对早期检测的需求和疾病的流行增加了对诊断服务的需求，从而推动了诊断检测设施的成长。这些设施对于提供广泛的诊断测试至关重要，包括生物标记评估和癌症筛检。此外，由于诊断技术的进步和对个人化医疗的重视，诊断测试实验室在医疗保健环境中的重要性日益增加。

占比最高的地区

在前列腺癌诊断方面，北美拥有最大的市场占有率。前列腺癌在该地区非常常见，该地区很早就引入了尖端诊断技术，而且医疗保健基础设施也很发达。此外，早期检测和诊断的可靠方法是强有力的筛检计划，例如 PSA 检测。北美的地位因其积极主动的癌症研究方法、强有力的政府支持以及高度的公众和专业意识而得到进一步加强。

复合年增长率最高的地区：

就前列腺癌诊断市场而言，亚太地区的复合年增长率最高。这一增长的推动因素包括前列腺癌发病率上升、早期检测的普及知识以及中国、印度和日本等国家不断发展的医疗保健系统。该地区高龄化和生活方式的改变是导致前列腺癌发病率上升的因素，也增加了对先进诊断试剂的需求。此外，政府措施、医疗保健投资以及与跨国诊断公司的合作正在加速尖端诊断技术的采用。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球前列腺癌诊断市场：依测试类型

  • 初步检查
    • PSA测试
    • 免费PSA测试
    • 总PSA测试
    • 其他初步测试
  • 确认检查
    • PCA3测试
    • 经直肠超音波检查
    • 切片检查测试
  • 免疫组织化学
  • 其他测试类型

第六章全球前列腺癌诊断市场：依癌症类型分类

  • 良性摄护腺增生症
  • 摄护腺癌
  • 小细胞癌
  • 其他类型的癌症

第七章全球前列腺癌诊断市场：依最终用户分类

  • 医院
  • 门诊设施
  • 诊断实验室
  • 癌症研究
  • 居家照护
  • 研究与製造
  • 其他最终用户

第八章全球前列腺癌诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Danaher Corporation
  • Abbott Laboratories
  • BioMerieux SA
  • F. Hoffman La Roche Ltd.
  • Bayer Aktiengesellschaft
  • Myriad Genetics Inc.
  • Genomic Health, Inc.
  • Agilent Technologies
  • Siemens Healthcare GmbH
  • Vyant Bio Inc.
  • Biocept Inc.
  • DiaSorin SpA
  • AstraZeneca Plc.
  • OPKO Health, Inc.
  • Becton Dickinson and Company
  • MDx Health
  • Foundation Medicine Inc.
  • Telo Genomics Corp（3D Signatures）
Product Code: SMRC24713

According to Stratistics MRC, the Global Prostate Cancer Diagnostics Market is accounted for $8.77 billion in 2023 and is expected to reach $15.25 billion by 2030 growing at a CAGR of 8.23% during the forecast period. In order to identify and describe prostate cancer in its early stages, prostate cancer diagnostics employ a multifaceted approach. Digital rectal examination (DRE), transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and the prostate-specific antigen (PSA) blood test are important diagnostic techniques. Moreover, the PSA test gauges the amount of a protein secreted by the prostate gland; high levels frequently signal the need for additional research. The evaluation of the prostate's size and texture is aided by a digital rectal examination.

According to the National Cancer Institute, in 2019, over 174,650 new cases of prostate cancer were diagnosed in the U.S. Additionally, data from the same source also suggests that over 31,620 deaths occurred in 2019 due to prostate cancer.

Market Dynamics:

Driver:

Growing prostate cancer incidence

Improved cancer detection techniques, aging populations, and altered lifestyles are the main causes of the prostate cancer incidence that has been rising steadily throughout the world. Furthermore, there is a growing need for sophisticated diagnostic tools that can precisely identify and characterize prostate cancer at its earliest stages, which is driving market growth as screening programs become more widely implemented and healthcare awareness increases.

Restraint:

Expensive neuroimaging equipment

Healthcare facilities face a major financial obstacle due to the prohibitive cost of sophisticated neuroimaging equipment, such as magnetic resonance imaging (MRI) machines. Access to advanced diagnostic tools may be restricted by the significant capital outlay necessary for purchasing and maintaining state-of-the-art machinery, especially in environments with limited resources. Additionally, it will take creative financing strategies and affordable substitutes to lessen this constraint.

Opportunity:

Technological developments in neuroimaging

The market is poised for substantial growth as long as neuroimaging technologies continue to progress. Advancements in diagnostic techniques like magnetoencephalography (MEG), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) present opportunities for increased sensitivity, resolution, and diagnostic power. Furthermore, putting money into research and development to incorporate these state-of-the-art technologies can lead to new opportunities for precise and thorough neuroimaging diagnosis.

Threat:

Threats from alternative diagnostic technologies

Traditional neuroimaging diagnostics are under threat from emerging alternative diagnostic technologies like wearable neurotechnology and cerebrospinal fluid biomarker analysis. Moreover, the market's established position is under threat from non-imaging modalities, so continued innovation and differentiation are necessary to stay relevant and hold onto market share.

COVID-19 Impact:

In the neuroimaging diagnostics market, the COVID-19 pandemic has had a significant effect. Healthcare services, such as regular diagnostic tests, elective screenings, and non-emergency medical visits, were disrupted by the abrupt start of the global health crisis. The application of social distancing measures and the allocation of resources to pandemic management led to a decrease in the use of neuroimaging diagnostics. Furthermore, healthcare facilities ability to make purchases was also impacted by supply chain disruptions and economic uncertainty, which caused delays in the purchase of cutting-edge imaging equipment.

The Prostatic Adenocarcinoma segment is expected to be the largest during the forecast period

The segment with the largest market share is prostate adenocarcinoma. The majority of cases of prostate cancer that are diagnosed are prostatic adenocarcinoma, which is the most common type of the disease. The prostate's glandular cells are the cancer's original site, and it can present in a variety of ways, both clinically and aggressively. Age, heredity, and hormonal influences are among the factors linked to the high incidence of prostatic adenocarcinoma. Moreover, prostatic adenocarcinoma is difficult to diagnose and characterize without the use of diagnostic techniques such as PSA testing, digital rectal examination (DRE), and advanced imaging technologies.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market, the segment with the highest CAGR is diagnostic laboratories. The need for early detection and rising disease prevalence are driving up demand for diagnostic services, which in turn is fueling the growth of diagnostic laboratories. These establishments are crucial in offering an extensive array of diagnostic examinations, such as biomarker evaluations and cancer screenings. Additionally, diagnostic laboratories are becoming increasingly important in the healthcare environment as a result of improvements in diagnostic technologies and a focus on personalized medicine.

Region with largest share:

Concerning prostate cancer diagnostics, North America holds the largest market share. Prostate cancer is very common in the area; cutting-edge diagnostic technologies were adopted early; and the region has a strong healthcare infrastructure. Furthermore, a reliable means of early detection and diagnosis is through robust screening programs, like PSA testing. Further strengthening North America's position is proactive approaches to cancer research, robust government backing, and high levels of public and professional awareness.

Region with highest CAGR:

In terms of the market for prostate cancer diagnostics, the Asia-Pacific region has the highest CAGR. The rising incidence of prostate cancer, growing knowledge of early detection, and the development of the healthcare system in nations like China, India, and Japan are some of the reasons driving this growth. The need for sophisticated diagnostics is being driven by the region's aging population and changing lifestyles, which are factors in the rising incidence of prostate cancer. Additionally, the adoption of cutting-edge diagnostic technologies is being accelerated by government initiatives, healthcare investments, and partnerships with multinational diagnostic companies.

Key players in the market:

Some of the key players in Prostate Cancer Diagnostics market include Danaher Corporation, Abbott Laboratories, BioMerieux SA, F. Hoffman La Roche Ltd., Bayer Aktiengesellschaft, Myriad Genetics Inc., Genomic Health, Inc., Agilent Technologies, Siemens Healthcare GmbH, Vyant Bio Inc., Biocept Inc., DiaSorin S.p.A, AstraZeneca Plc., OPKO Health, Inc., Becton Dickinson and Company, MDx Health, Foundation Medicine Inc. and Telo Genomics Corp (3D Signatures).

Key Developments:

In December 2023, Danaher Corp., a global life sciences and diagnostics provider based in Washington D.C., has completed its $5.7 billion acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. Abcam has become an indirect wholly owned subsidiary of Danaher. Danaher's Life Sciences businesses provide tools and technologies to support the advancement of pharmaceuticals and biopharmaceuticals.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Test Types Covered:

  • Preliminary Tests
  • Confirmatory Tests
  • Immunohistochemistry
  • Other Test Types

Cancer Types Covered:

  • Benign Prostatic Hyperplasia
  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma
  • Other Cancer Types

End Users Covered:

  • Hospitals
  • Outpatient Facilities
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Home Care
  • Research & Manufacturing
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prostate Cancer Diagnostics Market, By Test Type

  • 5.1 Introduction
  • 5.2 Preliminary Tests
    • 5.2.1 PSA Tests
    • 5.2.2 Free PSA Test
    • 5.2.3 Total PSA Test
    • 5.2.4 Other Preliminary Tests
  • 5.3 Confirmatory Tests
    • 5.3.1 Pca3 Test
    • 5.3.2 Trans-Rectal Ultrasound
    • 5.3.3 Biopsy Test
  • 5.4 Immunohistochemistry
  • 5.5 Other Test Types

6 Global Prostate Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Benign Prostatic Hyperplasia
  • 6.3 Prostatic Adenocarcinoma
  • 6.4 Small Cell Carcinoma
  • 6.5 Other Cancer Types

7 Global Prostate Cancer Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Outpatient Facilities
  • 7.4 Diagnostic Laboratories
  • 7.5 Cancer Research Institutes
  • 7.6 Home Care
  • 7.7 Research & Manufacturing
  • 7.8 Other End Users

8 Global Prostate Cancer Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Danaher Corporation
  • 10.2 Abbott Laboratories
  • 10.3 BioMerieux SA
  • 10.4 F. Hoffman La Roche Ltd.
  • 10.5 Bayer Aktiengesellschaft
  • 10.6 Myriad Genetics Inc.
  • 10.7 Genomic Health, Inc.
  • 10.8 Agilent Technologies
  • 10.9 Siemens Healthcare GmbH
  • 10.10 Vyant Bio Inc.
  • 10.11 Biocept Inc.
  • 10.12 DiaSorin S.p.A
  • 10.13 AstraZeneca Plc.
  • 10.14 OPKO Health, Inc.
  • 10.15 Becton Dickinson and Company
  • 10.16 MDx Health
  • 10.17 Foundation Medicine Inc.
  • 10.18 Telo Genomics Corp (3D Signatures)

List of Tables

  • Table 1 Global Prostate Cancer Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 4 Global Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 5 Global Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 6 Global Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 7 Global Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 8 Global Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 9 Global Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 10 Global Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 11 Global Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 12 Global Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 13 Global Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 14 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 15 Global Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 16 Global Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 17 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 18 Global Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 19 Global Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 21 Global Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 22 Global Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 23 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 24 Global Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 25 Global Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 26 Global Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 29 North America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 30 North America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 31 North America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 32 North America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 33 North America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 34 North America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 35 North America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 36 North America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 37 North America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 38 North America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 39 North America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 40 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 41 North America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 42 North America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 43 North America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 44 North America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 45 North America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 46 North America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 47 North America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 48 North America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 49 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 50 North America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 51 North America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 52 North America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 55 Europe Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 56 Europe Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 57 Europe Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 58 Europe Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 59 Europe Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 60 Europe Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 61 Europe Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 62 Europe Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 63 Europe Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 64 Europe Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 65 Europe Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 66 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 67 Europe Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 68 Europe Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 69 Europe Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 70 Europe Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 71 Europe Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 73 Europe Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 74 Europe Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 75 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 76 Europe Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 77 Europe Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 78 Europe Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 82 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 83 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 84 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 85 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 86 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 87 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 88 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 89 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 90 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 91 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 92 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 93 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 94 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 95 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 96 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 97 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 98 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 99 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 100 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 101 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 102 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 103 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 104 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 107 South America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 108 South America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 109 South America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 110 South America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 111 South America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 112 South America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 113 South America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 114 South America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 115 South America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 116 South America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 117 South America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 118 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 119 South America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 120 South America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 121 South America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 122 South America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 123 South America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 124 South America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 125 South America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 126 South America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 127 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 128 South America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 129 South America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 130 South America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
  • Table 134 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
  • Table 135 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
  • Table 136 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
  • Table 137 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
  • Table 138 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
  • Table 139 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
  • Table 140 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
  • Table 141 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
  • Table 142 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 143 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 144 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 145 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
  • Table 146 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
  • Table 147 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
  • Table 148 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 149 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 150 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 151 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
  • Table 152 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 153 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 154 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
  • Table 155 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
  • Table 156 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)